by Denkstrom
All storiesMore people on HIV treatment in Fund-supported countries despite cuts

More people on HIV treatment in Fund-supported countries despite cuts

In countries supported by the Global Fund, the number of people receiving HIV treatment rose to 26.9 million in 2025. At the same time, the number of people receiving a form of HIV prevention called PrEP fell.

¶ The Global Fund reports that 25.6 million people received antiretroviral therapy for HIV in the countries it supports in the previous year. In these countries, according to the Fund, 87 percent of people with HIV knew their status, 80 percent received treatment and 74 percent had suppressed viral loads.

The UN agency UNAIDS puts the decline in external financing for the global HIV response in low- and middle-income countries in 2025 at 18 percent compared with the previous year. According to the specialist publication Health Policy Watch, the gains were achieved despite cuts to global health aid since Donald Trump took office as US president in January 2025. According to NPR, some of these cuts affect the President's Emergency Plan for AIDS Relief, or PEPFAR; the US government said the program's restructuring was intended to end waste and dependence on foreign countries. According to NPR, a US State Department spokesperson said the new direct agreement with Mozambique's government protected American lives and strengthened Mozambique's ability to detect, prevent and control infectious diseases; the America First strategy had strengthened PEPFAR.

hiv

Whose success this is

The Fund itself stresses that, wherever possible, it reports the full national results of the countries it supports, thus showing the combined impact of all partners involved, not just its own projects. According to the Fund, attributing results to individual partners in a joint program leads to arbitrary assumptions because public health interventions are inherently interconnected.

Decline in prevention

Peter Sands, executive director of the Global Fund, said, according to Health Policy Watch, that the Fund had responded quickly and flexibly to protect the people and programs hardest hit by cuts, but acknowledged that some countries had managed the changes with little impact while others had been hit much harder, and that HIV prevention had suffered badly from cuts in domestic and international funding. Speaking to Avvenire, Sands described painful trade-offs: where lifesaving services had been protected, prevention had deteriorated; elsewhere, long-term investments had been affected.

Mozambique as an example

Mozambique shows how severely such cuts can affect services on the ground: according to the Global Fund's Office of the Inspector General, OIG, a US stop-work order issued on January 25, 2025, triggered the temporary layoffs of 20,000 health workers, including data entry staff and community health workers. Staff shortages and disruptions to sample transport affected viral load testing coverage among patients receiving antiretroviral therapy, according to the OIG. Mozambique nevertheless avoided major disruptions to HIV medicine supplies; according to the OIG, the Fund and a US waiver helped maintain availability. US-funded prevention services for key populations as well as adolescent girls and young women, however, were discontinued in February 2025; according to the OIG, adjusted Fund grants covered a limited portion of the lost services. The OIG notes that this information on program disruptions comes from third-party sources that were not independently validated and that it did not assess the effectiveness of the adjustments.

Those affected included DREAMS, a prevention initiative specifically for adolescent girls and young women that provided girls in Gaza province with books and school uniforms; DREAMS mentor Regina Mhabanga had recruited 80 girls for it. Mhabanga said the children had lost this opportunity, which had been painful for her as a worker in her own community. Arminda Nafungo, head of ACTIVA, announced that she would continue applying for funding from other partners; she also said she was encouraging people to continue prevention and treatment so that there would not be many lives lost before the project returned.

According to UNAIDS, an estimated 41.0 million people worldwide were living with HIV in 2025; the organization puts global treatment coverage at 78 percent, with an uncertainty range of 59 to 94 percent. The 80 percent reported by the Fund, however, refers to the countries it supports, not the world as a whole; the two figures therefore do not contradict each other, as they measure different populations. Children illustrate how unevenly progress is distributed: in 2025, there were 93,000 new HIV infections among children worldwide. Only 55 percent of the 1.3 million children living with HIV were receiving treatment, well below the rate among adults. Aktionsbündnis gegen AIDS also criticizes the Fund's report for providing only limited quantification of which specific services for communities have been lost or are at risk and what consequences this has for individual key populations; it warns that services for criminalized or marginalized people could be among the first to be cut when international funding ends.

¶ In its summary of the report, the organization Friends of The Global Fight points out that in 2010, only 22 percent of people with HIV in Fund-supported countries received antiretroviral therapy. Since 2002, AIDS-related deaths in these countries have fallen by 77 percent and new HIV infections by 64 percent, according to the Fund; Aktionsbündnis gegen AIDS cites the same figures in its summary of the report. In addition, 623,000 pregnant women with HIV in these countries received medicines in 2025 intended to protect their own lives and prevent transmission of the virus to their babies.

From 17.5 to 26.9 million people receiving treatment

¶ In 2017, the number of people receiving treatment in Fund-supported countries stood at 17.5 million. According to UNAIDS, the funding shifts prompted countries to prioritize mobilizing their own resources in the short term to maintain HIV treatment, which the organization considers a necessary first step toward safeguarding national responses to the epidemic. According to Health Policy Watch, Sands said they were working closely with countries to achieve nationally funded health systems independent of external support; speaking to Avvenire, he acknowledged that this transition was working for many countries, but that in contexts of extreme poverty, the resources for it were simply lacking. According to the Global Fund, the first deliveries of lenacapavir in late 2025 were already followed by an accelerated rollout of the HIV prevention medicine in 2026.